Bristol-Myers Squibb has announced that treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3 ELOQUENT-2 trial after four years of follow–up.
The follow–up data showed that Empliciti plus lenalidomide/dexamethasone can offer prolonged efficacy in patients with relapsed or refractory multiple myeloma, compared with lenalidomide/dexamethasone alone.
The combination therapy demonstrated a sustained reduction in risk of disease progression and death of 29%, as well as a 50% relative improvement in progression-free survival rates.
After the four-year period had elapsed, 21% of patients were still alive and disease-free, in contrast to the 14% of patients receiving Revlimid and dexamethasone (Ld) alone.
Empliciti is an immunostimulatory antibody that specifically binds to SLAMF7, a glycoprotein, or a protein attached to a carbohydrate group, located at the cell-surface. SLAMF7 is found in myeloma cells and in immune cell subsets.
The findings were presented at the 22nd Congress of the European Hematology Association in Madrid, Spain, and represent the longest follow-up assessment of efficacy and safety of an immuno-oncology drug.
Jonathan Leith, PhD, haematology development lead at Bristol-Myers Squibb, said: “The long-term efficacy data for Empliciti in patients with advanced multiple myeloma shows the combination of this immuno–oncology agent with standard Ld treatment can improve patient outcomes.”
Empliciti is being developed through a collaboration between Bristol-Myers Squibb and AbbVie, with Bristol-Myers Squibb solely responsible for commercial activities.